National Institute for Health and Clinical Excellence (NICE)
NICE launches online resource to help development and adoption of new health technologies
HealthTech Connect, a new online resource provided by NICE to help identify and support new health technologies as they move from inception to adoption in the UK health and care system was formally launched today (29 April).
Developed by NICE with help from a range of partner organisationsi and funding from NHS England, HealthTech Connect is for health technologies (medical devices and diagnostic and digital health technologies) that:
- offer measurable benefits to patients (or other health and care service users) compared to those already offered by current routine practice in the UK, or
- provide measurable benefits to the UK health and care system compared to those already offered by current routine practice in the UK.
The system, which is free to use, will help companies to understand what information is needed by decision makers in the UK health and care system, and clarify possible routes to market access. It will also help the UK health and care system to better plan for the introduction and adoption of health technologies - for example by reconfiguring services or enabling reimbursement.
Once registered, companies enter and update information about their technology as it develops into www.HealthTechConnect.org.uk. This information is used to determine if the technology is suitable for consideration by an organisation that offers support to health technology developers; for example with funding, technology development, evidence generation, market access, reimbursement, adoption.
It will also be used to identify if the technology is suitable for consideration for evaluation by a UK health technology assessment programme.
Technologies that are suitable for support or evaluation will be able to access this through HealthTech Connect. This will avoid companies having to provide the same or similar information about their technology separately to a different organisation or programme.
Meindert Boysen, director of the Centre for Health technology Evaluation at NICE, said: “HealthTech Connect is a clear and simple point of entry for companies developing health technologies, be it medical devices, diagnostics or digital health technologies, to access support and potential routes to national evaluation programmes.
“As well as helping national organisations like NICE, that have a responsibility for developing guidance on the use of health technologies in the NHS, better identify and track technologies that offer novel benefits, HealthTech Connect will also enable transformative technologies to be identified and fast tracked through relevant processes within the Accelerated Access Collaborative.
“Ultimately the aim of HealthTech Connect is to help get promising new health technologies to the people who will benefit from them, faster. We expect it to contribute to reducing the complexity, and often duplication, involved in getting medical devices, diagnostics and digital health technologies adopted in the UK.”
Since the initial “soft” launch of the system in February, over 100 companies have registered to use HealthTech Connect, 13 technologies have been submitted, and 1 technology [Sonata System] has already been selected by NICE for a Medtech Innovation Briefing
Sarah Field, sales manager UK & Ireland for Gynesonics, said: “The HealthTech Connect portal was a great way to interface the interaction between our organisation and NICE. This enabled a swift pathway for our new technology (the Sonata treatmentii) to be evaluated. I thoroughly recommend other commercial organisations to use this route. The registration process was quick and simple. This is a really helpful initiative.”
Further information about HealthTech Connect is available at the HealthTech Connect website
- ABHI, AXREM, BIVDA), NIHR and the NIHR Innovation Observatory, the AHSN network, Office for Life Sciences, MHRA, NHS Clinical Commissioners, NHS Supply chain and the devolved administrations in Wales, Scotland, and Northern Ireland.
- The Sonata System combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation in an incisionless procedure to treat symptomatic uterine fibroids.
Latest News from
National Institute for Health and Clinical Excellence (NICE)
NICE signs agreement with Colombia’s Institute of Health Technology Assessment to forge closer working ties10/07/2020 14:05:00
Research and knowledge sharing key to collaborative working approach agreed the two agencies
NICE’s strategy on sustainability: current progress and next steps10/07/2020 09:15:00
Fizzah Ali, NICE clinical fellow, outlines the key steps towards a sustainability strategy at NICE.
Innovation through HTA: theme for HTAi 2021 Annual Meeting announced06/07/2020 13:43:00
Health Technology Assessment International (HTAi) has announced the theme for the 2021 Annual Meeting which will be held from 19-23 June in Manchester.
Cancer patients to benefit from new histology independent treatment26/06/2020 16:15:00
Entrectinib (Rozlytrek, Roche), a revolutionary treatment for a range of cancers, is the second histology independent drug to be recommended by NICE for use on the Cancer Drugs Fund (CDF).
Steam treatment recommended for men with an enlarged prostate25/06/2020 16:15:00
Minimally invasive procedure involves injecting steam to destroy excess prostate tissue.
NICE draft guidance does not recommend siponimod for treating secondary progressive multiple sclerosis25/06/2020 13:43:00
NICE has today (25 June 2020) issued draft guidance for public consultation which does not recommend siponimod (also called Mayzent and made by Novartis) for treating secondary progressive multiple sclerosis (MS).
NICE begins phased restart of non-COVID-19 guidance25/06/2020 09:15:00
NICE has begun a phased restart of publishing non-COVID-19 guidance as the NHS and wider health and care system start to return to normal arrangements.
NICE publishes latest COVID-19 guidance on renal transplantation22/06/2020 09:15:00
NICE has published new rapid COVID-19 guidance for children, young people and adults who need or who have had a kidney transplant, and people who are donating a kidney (live donors).